Hao Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hao Zhang has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Shuqi Hu
Department of Neurology, Affiliated Hangzhou First People’s Hospital, Westlake University School of Medicine, Hangzhou, China
6 shared publicationsBingjie Yang
Department of Neurology, The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou First People's Hospital, Hangzhou, Zhejiang, China
5 shared publicationsJiahui Zhu
Department of Neurology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China
4 shared publicationsSong Shu
Department of Neurology, Affiliated Hangzhou First People’s Hospital, Westlake University School of Medicine, Hangzhou, China
4 shared publicationsXuemei Fan
Department of Neurology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China
4 shared publicationsYijie Dai
Department of Neurology, Hangzhou First People's Hospital, Hangzhou, China
3 shared publications
Latest Publications
- Open Access
- 24 October 2026
- Published by Wolters Kluwer Health in Neural Regeneration Research
Constructing functional neural circuits to model amyotrophic lateral sclerosis with induced pluripotent stem cell-derived brain organoids
Amyotrophic lateral sclerosis is a progressive neurodegenerative disease characterized by the degeneration of both upper and lower motor neurons. Recent advances in human-induced pluripotent stem cell-derived brain organoids offer an innovative platform to model amyotrophic lateral sclerosis in a human-specific context. These three-dimensional organoid systems allow for the study of neuronal circuit-level dysfunction, which is central to amyotrophic lateral sclerosis pathogenesis, by incorporating multiple neuronal subtypes and supporting glial populations. In particular, the integration of region-specific brain organoids into assembloid models has enabled the reconstruction of functional long-range projections and cortico-motor circuits, closely resembling human neural connectivity. This review summarizes the generation and application of human induced pluripotent stem cell-derived brain organoids for amyotrophic lateral sclerosis research, with a focus on the reconstruction of neural circuits, multi-omics profiling, and functional assays. We also discuss how organoid systems can be leveraged for drug discovery and personalized medicine in amyotrophic lateral sclerosis, highlighting their potential to unveil human-specific disease mechanisms. Lastly, we address the current challenges and future directions for improving the physiological relevance of organoid models in amyotrophic lateral sclerosis research.
- 24 October 2026
- Published by Wolters Kluwer Health in Neural Regeneration Research
Open AccessConstructing functional neural circuits to model amyotrophic lateral sclerosis with induced pluripotent stem cell-derived brain organoids
Amyotrophic lateral sclerosis is a progressive neurodegenerative disease characterized by the degeneration of both upper and lower motor neurons. Recent advances in human-induced pluripotent stem cell-derived brain organoids offer an innovative platform to model amyotrophic lateral sclerosis in a human-specific context. These three-dimensional organoid systems allow for the study of neuronal circuit-level dysfunction, which is central to amyotrophic lateral sclerosis pathogenesis, by incorporating multiple neuronal subtypes and supporting glial populations. In particular, the integration of region-specific brain organoids into assembloid models has enabled the reconstruction of functional long-range projections and cortico-motor circuits, closely resembling human neural connectivity. This review summarizes the generation and application of human induced pluripotent stem cell-derived brain organoids for amyotrophic lateral sclerosis research, with a focus on the reconstruction of neural circuits, multi-omics profiling, and functional assays. We also discuss how organoid systems can be leveraged for drug discovery and personalized medicine in amyotrophic lateral sclerosis, highlighting their potential to unveil human-specific disease mechanisms. Lastly, we address the current challenges and future directions for improving the physiological relevance of organoid models in amyotrophic lateral sclerosis research.
- 14 September 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (9) , 1-13
Evaluating the predictive potential of Th1 (IFN-γ+CD4+)/CD4+ in rapidly progressive amyotrophic lateral sclerosis
Background Th1 (IFN-γ+CD4+)/CD4+ cells exacerbate the release of pro-inflammatory cytokines, contributing to neuronal death. It is proposed that the peripheral immune system plays a pivotal role in the pathophysiology of amyotrophic lateral sclerosis (ALS). This study aims to develop an interpretable machine learning model based on blood Th1/CD4+ cells to predict rapidly progressive ALS. Methods We enrolled 564 patients with sporadic ALS who met the eligibility inclusion criteria for further analysis. Immune cells and cytokines were quantified using flow cytometric cell counting and a flow cytometry-based fluorescent bead capture assay. Multivariate Cox proportional hazards models and restricted cubic spline analyses were applied to estimate the correlation between Th1/CD4+ cells and rapidly progressive ALS. The important variables identified through LASSO regression analysis were incorporated into the development of the machine learning model. Results The multivariate Cox proportional hazards model revealed that, compared to the low Th1/CD4+ group (Th1/CD4+ < 16.21), the high Th1/CD4+ group (Th1/CD4+ ≥ 16.21) was positively associated with the rate of ALS progression (HR: 1.90, 95% CI: 1.34–2.70). Th1/CD4+ is also associated with the decline in forced vital capacity (r = 0.11, P = 0.01). The machine learning model was built using Th1/CD4+ in combination with the other 4 features. Xgboost performed best in the validation cohort, achieving an AUC of 0.804 and a G mean of 0.756. Conclusions Th1/CD4+ (with an optimal cutoff value of 16.21) was established as an independent risk factor for rapid progression in ALS. The machine learning model incorporating Th1/CD4+ demonstrated strong predictive performance. Trial registration The prospective cohort study is registered with the Chinese Clinical Trial Registry (ID: ChiCTR2400079885) (http://www.chictr.org.cn/).
- 14 September 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (9) , 1-13
Evaluating the predictive potential of Th1 (IFN-γ+CD4+)/CD4+ in rapidly progressive amyotrophic lateral sclerosis
Background Th1 (IFN-γ+CD4+)/CD4+ cells exacerbate the release of pro-inflammatory cytokines, contributing to neuronal death. It is proposed that the peripheral immune system plays a pivotal role in the pathophysiology of amyotrophic lateral sclerosis (ALS). This study aims to develop an interpretable machine learning model based on blood Th1/CD4+ cells to predict rapidly progressive ALS. Methods We enrolled 564 patients with sporadic ALS who met the eligibility inclusion criteria for further analysis. Immune cells and cytokines were quantified using flow cytometric cell counting and a flow cytometry-based fluorescent bead capture assay. Multivariate Cox proportional hazards models and restricted cubic spline analyses were applied to estimate the correlation between Th1/CD4+ cells and rapidly progressive ALS. The important variables identified through LASSO regression analysis were incorporated into the development of the machine learning model. Results The multivariate Cox proportional hazards model revealed that, compared to the low Th1/CD4+ group (Th1/CD4+ < 16.21), the high Th1/CD4+ group (Th1/CD4+ ≥ 16.21) was positively associated with the rate of ALS progression (HR: 1.90, 95% CI: 1.34–2.70). Th1/CD4+ is also associated with the decline in forced vital capacity (r = 0.11, P = 0.01). The machine learning model was built using Th1/CD4+ in combination with the other 4 features. Xgboost performed best in the validation cohort, achieving an AUC of 0.804 and a G mean of 0.756. Conclusions Th1/CD4+ (with an optimal cutoff value of 16.21) was established as an independent risk factor for rapid progression in ALS. The machine learning model incorporating Th1/CD4+ demonstrated strong predictive performance. Trial registration The prospective cohort study is registered with the Chinese Clinical Trial Registry (ID: ChiCTR2400079885) (http://www.chictr.org.cn/).
- 2 April 2024
- Published by Springer Nature in Molecular Neurobiology
- Vol. 61 (11) , 8797-8819
Advancements in Single-Cell RNA Sequencing Research for Neurological Diseases
Neurological diseases are a major cause of the global burden of disease. Although the mechanisms of the occurrence and development of neurological diseases are not fully clear, most of them are associated with cells mediating neuroinflammation. Yet medications and other therapeutic options to improve treatment are still very limited. Single-cell RNA sequencing (scRNA-seq), as a delightfully potent breakthrough technology, not only identifies various cell types and response states but also uncovers cell-specific gene expression changes, gene regulatory networks, intercellular communication, and cellular movement trajectories, among others, in different cell types. In this review, we describe the technology of scRNA-seq in detail and discuss and summarize the application of scRNA-seq in exploring neurological diseases, elaborating the corresponding specific mechanisms of the diseases as well as providing a reliable basis for new therapeutic approaches. Finally, we affirm that scRNA-seq promotes the development of the neuroscience field and enables us to have a deeper cellular understanding of neurological diseases in the future, which provides strong support for the treatment of neurological diseases and the improvement of patients’ prognosis.
- 2 April 2024
- Published by Springer Nature in Molecular Neurobiology
- Vol. 61 (11) , 8797-8819
Advancements in Single-Cell RNA Sequencing Research for Neurological Diseases
Neurological diseases are a major cause of the global burden of disease. Although the mechanisms of the occurrence and development of neurological diseases are not fully clear, most of them are associated with cells mediating neuroinflammation. Yet medications and other therapeutic options to improve treatment are still very limited. Single-cell RNA sequencing (scRNA-seq), as a delightfully potent breakthrough technology, not only identifies various cell types and response states but also uncovers cell-specific gene expression changes, gene regulatory networks, intercellular communication, and cellular movement trajectories, among others, in different cell types. In this review, we describe the technology of scRNA-seq in detail and discuss and summarize the application of scRNA-seq in exploring neurological diseases, elaborating the corresponding specific mechanisms of the diseases as well as providing a reliable basis for new therapeutic approaches. Finally, we affirm that scRNA-seq promotes the development of the neuroscience field and enables us to have a deeper cellular understanding of neurological diseases in the future, which provides strong support for the treatment of neurological diseases and the improvement of patients’ prognosis.
- Open Access
- 9 January 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 10, 1302460
The association between serum heat shock protein 72 and intestinal permeability with intestinal microbiota and clinical severity in patients with cerebral infarction
Objectives: We aimed to compare serum heat shock protein 72 (HSP72) and intestinal permeability in patients with cerebral infarction (CI) and healthy individuals to reveal their correlations and link to gut microbiota alterations and clinical severity of CI.Methods and results: Stool samples of 50 patients with CI and 46 healthy volunteers were analyzed through 16S rRNA gene sequencing to characterize intestinal flora profiles. Serum HSP72 and zonulin were assayed using enzyme-linked immunoassay (ELISA). The obtained data were then subjected to comparative and correlative analysis. We found that the levels of zonulin and serum HSP72 were significantly higher in the CI group compared to the healthy group. Serum HSP72 and zonulin levels were positively correlated in the CI group and correlated positively with the clinical severity of CI. β diversity showed significant differences in intestinal microbiota composition between the two groups. In the CI patient group, the abundance of bacteria Eubacterium_fissicatena_group, Eubacterium_eligens_group, and Romboutsia manifested a remarkably positive correlation with serum HSP72. The abundance of bacteria Eubacterium_fissicatena_group and Acetivibrio had a significantly positive correlation with zonulin levels.Conclusion: Our findings indicated that an increase in serum HSP72 and zonulin levels was manifested in patients with CI and was related to specific gut microbiota alterations and the clinical severity of CI.
- 9 January 2024
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 10, 1302460
Open AccessThe association between serum heat shock protein 72 and intestinal permeability with intestinal microbiota and clinical severity in patients with cerebral infarction
Objectives: We aimed to compare serum heat shock protein 72 (HSP72) and intestinal permeability in patients with cerebral infarction (CI) and healthy individuals to reveal their correlations and link to gut microbiota alterations and clinical severity of CI.Methods and results: Stool samples of 50 patients with CI and 46 healthy volunteers were analyzed through 16S rRNA gene sequencing to characterize intestinal flora profiles. Serum HSP72 and zonulin were assayed using enzyme-linked immunoassay (ELISA). The obtained data were then subjected to comparative and correlative analysis. We found that the levels of zonulin and serum HSP72 were significantly higher in the CI group compared to the healthy group. Serum HSP72 and zonulin levels were positively correlated in the CI group and correlated positively with the clinical severity of CI. β diversity showed significant differences in intestinal microbiota composition between the two groups. In the CI patient group, the abundance of bacteria Eubacterium_fissicatena_group, Eubacterium_eligens_group, and Romboutsia manifested a remarkably positive correlation with serum HSP72. The abundance of bacteria Eubacterium_fissicatena_group and Acetivibrio had a significantly positive correlation with zonulin levels.Conclusion: Our findings indicated that an increase in serum HSP72 and zonulin levels was manifested in patients with CI and was related to specific gut microbiota alterations and the clinical severity of CI.
- 11 May 2023
- Published by Springer Nature in NeuroMolecular Medicine
- Vol. 25 (4) , 457-470
Targeting Pericytes for Functional Recovery in Ischemic Stroke
Pericytes surrounding endothelial cells in the capillaries are emerging as an attractive cell resource, which can show a large variety of functions in ischemic stroke, including preservation of the blood–brain barrier, regulation of immune function, and support for cerebral vasculature. These functions have been fully elucidated in previous studies. However, in recent years, increasing evidence has shown that pericytes play an important role in neurological recovery after ischemic stroke due to their regenerative function which can be summarized in two aspects according to current discoveries, one is that pericytes are thought to be multipotential themselves, and the other is that pericytes can promote the differentiation of oligodendrocyte progenitor cells (OPCs). Considering the neuroprotective treatment for stroke has not been much progressed in recent years, new therapies targeting pericytes may be a future direction. Here, we will review the beneficial effects of pericytes in ischemic stroke from two directions: the barrier and vascular functions and the regenerative functions of pericytes.
- 11 May 2023
- Published by Springer Nature in NeuroMolecular Medicine
- Vol. 25 (4) , 457-470
Targeting Pericytes for Functional Recovery in Ischemic Stroke
Pericytes surrounding endothelial cells in the capillaries are emerging as an attractive cell resource, which can show a large variety of functions in ischemic stroke, including preservation of the blood–brain barrier, regulation of immune function, and support for cerebral vasculature. These functions have been fully elucidated in previous studies. However, in recent years, increasing evidence has shown that pericytes play an important role in neurological recovery after ischemic stroke due to their regenerative function which can be summarized in two aspects according to current discoveries, one is that pericytes are thought to be multipotential themselves, and the other is that pericytes can promote the differentiation of oligodendrocyte progenitor cells (OPCs). Considering the neuroprotective treatment for stroke has not been much progressed in recent years, new therapies targeting pericytes may be a future direction. Here, we will review the beneficial effects of pericytes in ischemic stroke from two directions: the barrier and vascular functions and the regenerative functions of pericytes.
- Open Access
- 21 February 2023
- Published by Springer Nature in Research Square
The Association of Serum Heat Shock Protein 72 and Intestinal Permeability with Intestinal Microbiota and Clinical Severity in Patients with Cerebral Infarction
Purpose This study aimed to investigate the comparison and relationship between serum heat shock protein 72 (sHSP72) and intestinal permeability in patients with cerebral infarction (CI) and healthy individuals to elucidate the link to gut microbiota alterations and clinical severity of CI. Methods Stool samples of 50 CI patients and 46 healthy volunteers were applied to characterize intestinal flora profile through 16S rRNA gene sequencing. Composition difference and taxon evaluation were observed. sHSP72 and zonulin were assayed using enzyme-linked immunoassay (ELISA). Medical comorbidities and dietary habits were acquired using questionnaires and partial biochemical index were recorded. The obtained data were then subjected to comparative and correlative analysis. Results We found that the levels of zonulin and sHSP72 were significantly higher in CI group compared to the healthy group. Strikingly, sHSP72 and zonulin levels were positively correlated in CI group. After adjustment for age, gender, medical comorbidities and biochemical index, sHSP72 and zonulin levels correlated positively with clinical severity of CI. In the CI patient group, the abundance of bacteria Eubacterium_fissicatena_group, Eubacterium_eligens_group and Romboutsia manifested remarkably positive correlation with sHSP72. The abundance of bacteria Eubacterium_fissicatena_group and Acetivibrio were significantly positive correlation with zonulin levels. The CI group had a decreased abundance of Eubacterium_fissicatena_group, Eubacterium_eligens_group and Romboutsia, and an increased abundance of Acetivibrio. Conclusion Our findings represented that an increase in sHSP72 and zonulin levels were manifested in patients with CI and related to specific gut microbiota alterations and the clinical severity of CI.
- 21 February 2023
- Published by Springer Nature in Research Square
Open AccessThe Association of Serum Heat Shock Protein 72 and Intestinal Permeability with Intestinal Microbiota and Clinical Severity in Patients with Cerebral Infarction
Purpose This study aimed to investigate the comparison and relationship between serum heat shock protein 72 (sHSP72) and intestinal permeability in patients with cerebral infarction (CI) and healthy individuals to elucidate the link to gut microbiota alterations and clinical severity of CI. Methods Stool samples of 50 CI patients and 46 healthy volunteers were applied to characterize intestinal flora profile through 16S rRNA gene sequencing. Composition difference and taxon evaluation were observed. sHSP72 and zonulin were assayed using enzyme-linked immunoassay (ELISA). Medical comorbidities and dietary habits were acquired using questionnaires and partial biochemical index were recorded. The obtained data were then subjected to comparative and correlative analysis. Results We found that the levels of zonulin and sHSP72 were significantly higher in CI group compared to the healthy group. Strikingly, sHSP72 and zonulin levels were positively correlated in CI group. After adjustment for age, gender, medical comorbidities and biochemical index, sHSP72 and zonulin levels correlated positively with clinical severity of CI. In the CI patient group, the abundance of bacteria Eubacterium_fissicatena_group, Eubacterium_eligens_group and Romboutsia manifested remarkably positive correlation with sHSP72. The abundance of bacteria Eubacterium_fissicatena_group and Acetivibrio were significantly positive correlation with zonulin levels. The CI group had a decreased abundance of Eubacterium_fissicatena_group, Eubacterium_eligens_group and Romboutsia, and an increased abundance of Acetivibrio. Conclusion Our findings represented that an increase in sHSP72 and zonulin levels were manifested in patients with CI and related to specific gut microbiota alterations and the clinical severity of CI.
- Open Access
- 22 December 2022
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 15, 1050837
Research advances in cGAS–stimulator of interferon genes pathway and central nervous system diseases: Focus on new therapeutic approaches
Cyclic GMP–AMP synthase (cGAS), a crucial innate immune sensor, recognizes cytosolic DNA and induces stimulator of interferon genes (STING) to produce type I interferon and other proinflammatory cytokines, thereby mediating innate immune signaling. The cGAS–STING pathway is involved in the regulation of infectious diseases, anti-tumor immunity, and autoimmune diseases; in addition, it plays a key role in the development of central nervous system (CNS) diseases. Therapeutics targeting the modulation of cGAS–STING have promising clinical applications. Here, we summarize the cGAS–STING signaling mechanism and the recent research on its role in CNS diseases.
- 22 December 2022
- Published by Frontiers Media SA in Frontiers in Molecular Neuroscience
- Vol. 15, 1050837
Open AccessResearch advances in cGAS–stimulator of interferon genes pathway and central nervous system diseases: Focus on new therapeutic approaches
Cyclic GMP–AMP synthase (cGAS), a crucial innate immune sensor, recognizes cytosolic DNA and induces stimulator of interferon genes (STING) to produce type I interferon and other proinflammatory cytokines, thereby mediating innate immune signaling. The cGAS–STING pathway is involved in the regulation of infectious diseases, anti-tumor immunity, and autoimmune diseases; in addition, it plays a key role in the development of central nervous system (CNS) diseases. Therapeutics targeting the modulation of cGAS–STING have promising clinical applications. Here, we summarize the cGAS–STING signaling mechanism and the recent research on its role in CNS diseases.
- Open Access
- 12 August 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 967300
Host-microbiota interactions: The aryl hydrocarbon receptor in the acute and chronic phases of cerebral ischemia
The relationship between gut microbiota and brain function has been studied intensively in recent years, and gut microbiota has been linked to a couple of neurological disorders including stroke. There are multiple studies linking gut microbiota to stroke in the “microbiota-gut-brain” axis. The aryl hydrocarbon receptor (AHR) is an important mediator of acute ischemic damage and can result in subsequent neuroinflammation. AHR can affect these responses by sensing microbiota metabolites especially tryptophan metabolites and is engaged in the regulation of acute ischemic brain injury and chronic neuroinflammation after stroke. As an important regulator in the “microbiota-gut-brain” axis, AHR has the potential to be used as a new therapeutic target for ischemic stroke treatment. In this review, we discuss the research progress on AHR regarding its role in ischemic stroke and prospects to be used as a therapeutic target for ischemic stroke treatment, aiming to provide a potential direction for the development of new treatments for ischemic stroke.
- 12 August 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 967300
Open AccessHost-microbiota interactions: The aryl hydrocarbon receptor in the acute and chronic phases of cerebral ischemia
The relationship between gut microbiota and brain function has been studied intensively in recent years, and gut microbiota has been linked to a couple of neurological disorders including stroke. There are multiple studies linking gut microbiota to stroke in the “microbiota-gut-brain” axis. The aryl hydrocarbon receptor (AHR) is an important mediator of acute ischemic damage and can result in subsequent neuroinflammation. AHR can affect these responses by sensing microbiota metabolites especially tryptophan metabolites and is engaged in the regulation of acute ischemic brain injury and chronic neuroinflammation after stroke. As an important regulator in the “microbiota-gut-brain” axis, AHR has the potential to be used as a new therapeutic target for ischemic stroke treatment. In this review, we discuss the research progress on AHR regarding its role in ischemic stroke and prospects to be used as a therapeutic target for ischemic stroke treatment, aiming to provide a potential direction for the development of new treatments for ischemic stroke.